tiprankstipranks
Trending News
More News >
Clover Health Investments (CLOV)
NASDAQ:CLOV
US Market

Clover Health Investments (CLOV) Earnings Dates, Call Summary & Reports

Compare
3,379 Followers

Earnings Data

Report Date
Aug 11, 2025
TBA Not Confirmed
Period Ending
2025 (Q2)
Consensus EPS Forecast
>-0.01
Last Year’s EPS
0.01
Same Quarter Last Year
Moderate Buy
Based on 4 Analysts Ratings
---

Earnings Call Summary

Earnings Call Date:May 06, 2025
|
% Change Since: 0.00%
|
Next Earnings Date:Aug 11, 2025
Earnings Call Sentiment|Positive
The earnings call depicted a largely positive outlook for Clover Health, marked by significant growth in membership, revenue, and adjusted EBITDA. The company effectively highlighted its successful initiatives and technological advancements with Clover Assistant. Financial metrics showed considerable improvement, and the positive CMS rate notice added to the optimistic future outlook. However, there were some challenges with elevated inpatient utilization and past operational issues with claims payable, but these were minor in comparison to the overall robust performance.
Company Guidance
During Clover Health's first quarter 2025 earnings call, the company provided robust guidance reflecting significant growth and operational efficiency. Key metrics highlighted included a 30% increase in Medicare Advantage (MA) membership, 33% revenue growth, and a remarkable 279% improvement in adjusted EBITDA year-over-year. Adjusted net income also surged by 322%. The company reconfirmed its full-year 2025 guidance, expecting MA membership to average between 103,000 and 107,000, with insurance revenue projected between $1.8 billion and $1.875 billion. They anticipate adjusted SG&A to be between $355 million and $365 million, with adjusted EBITDA and net income now forecasted between $50 million and $70 million each. Insurance Benefit Expense Ratio (BER) is expected to range from 87% to 88%. Clover Health is optimistic about continuing its momentum into the rest of the year, driven by strategic investments in technology, specifically the Clover Assistant, and growth in their Clover Home Care Services and Counterpart Health strategy.
Significant Growth in Medicare Advantage Membership
The company reported a 30% increase in Medicare Advantage membership year-over-year, which contributed to strong revenue growth.
Robust Revenue and Adjusted EBITDA Growth
Revenue grew by 33% year-over-year, and adjusted EBITDA increased by a substantial 279%, reflecting the company's operational momentum.
Clover Assistant's Positive Impact
The Clover Assistant technology has been instrumental in improving health outcomes, including earlier diagnoses of diseases like chronic kidney disease and diabetes, and reducing hospitalizations for congestive heart failure.
Improved Financial Metrics
Adjusted net income grew by 322% year-over-year, and adjusted SG&A as a percentage of total revenue decreased by 360 basis points.
Successful Stock Buyback Program
The company successfully repurchased 5 million shares, completing the remaining $80 million authorized under its buyback program.
Positive CMS Final Rate Notice for 2026
The recent CMS final rate notice is expected to add momentum, especially with the introduction of a 4 Star PPO plan.
---

Clover Health Investments (CLOV) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

CLOV Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Aug 11, 20252025 (Q2)
-0.02 / -
0.01
May 06, 20252025 (Q1)
-0.04 / 0.05
-0.05206.00% (+0.10)
Feb 27, 20252024 (Q4)
-0.07 / -0.04
-0.14672.60% (+0.11)
Nov 06, 20242024 (Q3)
-0.04 / -0.02
-0.08676.74% (+0.07)
Aug 05, 20242024 (Q2)
-0.05 / 0.01
-0.06116.67% (+0.07)
May 07, 20242024 (Q1)
-0.07 / -0.05
-0.15267.11% (+0.10)
Mar 12, 20242023 (Q4)
-0.14 / -0.15
-0.17617.05% (+0.03)
Nov 06, 20232023 (Q3)
-0.11 / -0.09
-0.15845.57% (+0.07)
Aug 08, 20232023 (Q2)
-0.14 / -0.06
-0.21972.60% (+0.16)
May 09, 20232023 (Q1)
-0.17 / -0.15
-0.165.00% (<+0.01)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---

CLOV Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
May 06, 2025$3.35$3.77+12.54%
Feb 27, 2025$4.14$3.97-4.11%
Nov 06, 2024$4.35$3.67-15.63%
Aug 05, 2024$1.88$1.83-2.66%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---

FAQ

When does Clover Health Investments (CLOV) report earnings?
Clover Health Investments (CLOV) is schdueled to report earning on Aug 11, 2025, TBA Not Confirmed.
    What is Clover Health Investments (CLOV) earnings time?
    Clover Health Investments (CLOV) earnings time is at Aug 11, 2025, TBA Not Confirmed.
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is CLOV EPS forecast?
          CLOV EPS forecast for the fiscal quarter 2025 (Q2) is >-0.01.
            ---

            Clover Health Investments (CLOV) Earnings News

            Clover Health Gains on Robust Q4
            Premium
            Market News
            Clover Health Gains on Robust Q4
            2y ago
            Clover Health (NASDAQ:CLOV) Stock Rises on Q3 Beat
            Premium
            Market News
            Clover Health (NASDAQ:CLOV) Stock Rises on Q3 Beat
            2y ago
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis